1-4 of 4
Zuomei Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

Anne Roulston, Michal Zimmermann, Robert Papp, Alexander Skeldon, Charles Pellerin, Émilie Dumas-Bérube, Valerie Dumais, Stéphane Dorich, Lee D. Fader, Sara Fournier, Li Li, Marie-Eve Leclaire, Shou Yun Yin, Amandine Chefson, Hunain Alam, William Yang, Chloe Fugère-Desjardins, Sabrina Vignini-Hammond, Kathryn Skorey, Amina Mulani, Victoria Rimkunas, Artur Veloso, Martine Hamel, Rino Stocco, Yael Mamane, Zuomei Li, Jordan T.F. Young, Michael Zinda, W. Cameron Black
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (2): 245–256.
https://doi.org/10.1158/1535-7163.MCT-21-0615
Published: 01 February 2022
View article titled, RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Open the PDF for RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract P054: RP-3500: A novel, potent and selective ATR inhibitor that is effective in pre-clinical models as a monotherapy and in combination with PARP inhibitors

Anne Roulston, Michal Zimmerman, Robert Papp, Alex Skeldon, Charles Pellerin, Émilie Dumas-Bérube, Valerie Dumais, Stephane Dorich, Sara Fournier, Li Li, Marie-Ève Leclaire, Shou Yun Yin, Amandine Chefson, Hunain Alam, William Yang, Chloe Fugère-Desjardins, Sabrina Hammond, Kathryn Skorey, Amina Mulani, Victoria Rimkunas, Artur Veloso, Martine Hamel, Rino Stocco, Yael Mamane, Zuomei Li, Jordan Young, Mike Zinda, Cameron Black
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P054.
https://doi.org/10.1158/1535-7163.TARG-21-P054
Published: 01 December 2021
View article titled, Abstract P054: RP-3500: A novel, potent and selective ATR inhibitor that is effective in pre-clinical models as a monotherapy and in combination with PARP inhibitors
Journal Articles

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Marielle Fournel, Claire Bonfils, Yu Hou, Pu Theresa Yan, Marie-Claude Trachy-Bourget, Ann Kalita, Jianhong Liu, Ai-Hua Lu, Nancy Z. Zhou, Marie-France Robert, Jeffrey Gillespie, James J. Wang, Hélène Ste-Croix, Jubrail Rahil, Sylvain Lefebvre, Oscar Moradei, Daniel Delorme, A. Robert MacLeod, Jeffrey M. Besterman, Zuomei Li
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (4): 759–768.
https://doi.org/10.1158/1535-7163.MCT-07-2026
Published: 15 April 2008
View article titled, MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <em>in vitro</em> and <em>in vivo</em>
Open the PDF for MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <em>in vitro</em> and <em>in vivo</em> in another window
Includes: Supplementary data
Journal Articles

Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine in patients with refractory solid tumors

Herbert Hurwitz, Emily Chan, Peter O'Dwyer, Nashat Gabrail, Zuomei Li, Ann Kalita, MC Trachy Bourget, Manal Tawashi, R. Martell, R. Ward
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B139.
Published: 01 November 2007
View article titled, Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine in patients with refractory solid tumors